We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ardelyx Inc (ARDX) USD0.0001

Sell:$4.60 Buy:$5.29 Change: $0.22 (4.63%)
NASDAQ:0.05%
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$4.60
Buy:$5.29
Change: $0.22 (4.63%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$4.60
Buy:$5.29
Change: $0.22 (4.63%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Contact details

Address:
34175 Ardenwood Blvd.
FREMONT
94555
United States
Telephone:
+1 (510) 7457047
Website:
https://www.ardelyx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ARDX
ISIN:
US0396971071
Market cap:
$1.10 billion
Shares in issue:
236.85 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Michael Raab
    President, Chief Executive Officer, Director
  • Justin Renz
    Chief Financial and Operations Officer
  • Mike Kelliher
    Executive Vice President, Corporate Development and Strategy
  • Joseph Reilly
    Principal Accounting Officer
  • Elizabeth Grammer
    Chief Legal and Administrative Officer
  • Robert Blanks
    Chief Regulatory Affairs and Quality Assurance Officer
  • Eric Foster
    Chief Commercial Officer
  • David Rosenbaum
    Chief Development Officer
  • Laura Williams
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.